Rise of the planet of rare anemias: An update on emerging treatment strategies

被引:8
作者
Fattizzo, Bruno [1 ,2 ]
Motta, Irene [3 ,4 ]
机构
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, SC Ematol, Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, SC Med Indirizzo Metab, Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
关键词
beta-thalassemia; sickle cell disease; congenital hemolytic anemias; pyruvate kinase deficiency; autoimmune hemolytic anemia; cold agglutinin disease; paroxysmal nocturnal hemoglobinuria; aplastic anemia; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PHASE-3; TRIAL; ELTROMBOPAG; IMMUNOSUPPRESSION; ECULIZUMAB; INHIBITOR; MITAPIVAT;
D O I
10.3389/fmed.2022.1097426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic options for rare congenital (hemoglobinopathies, membrane and enzyme defects, congenital dyserythropoietic anemia) and acquired anemias [warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease CAD, paroxysmal nocturnal hemoglobinuria (PNH), and aplastic anemia (AA)] are rapidly expanding. The use of luspatercept, mitapivat and etavopivat in beta-thalassemia and pyruvate kinase deficiency (PKD) improves transfusion dependence, alleviating iron overload and long-term complications. Voxelotor, mitapivat, and etavopivat reduce vaso-occlusive crises in sickle cell disease (SCD). Gene therapy represents a fascinating approach, although patient selection, the toxicity of the conditioning regimens, and the possible long-term safety are still open issues. For acquired forms, wAIHA and CAD will soon benefit from targeted therapies beyond rituximab, including B-cell/plasma cell targeting agents (parsaclisib, rilzabrutinib, and isatuximab for wAIHA), complement inhibitors (pegcetacoplan and sutimlimab for CAD, ANX005 for wAIHA with complement activation), and inhibitors of extravascular hemolysis in the reticuloendothelial system (fostamatinib and FcRn inhibitors in wAIHA). PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan). These drugs have the potential to improve patient convenience and ameliorate residual anemia, although patient compliance becomes pivotal, and long-term safety requires further investigation. Finally, the addition of eltrombopag significantly ameliorated AA outcomes, and data regarding the alternative agent romiplostim are emerging. The accelerated evolution of treatment strategies will need further effort to identify the best candidate for each treatment in the precision medicine era.
引用
收藏
页数:11
相关论文
共 68 条
  • [1] Al-Samkari H., 2022, HEMASPHERE, V6, P1424, DOI [10.1097/01.HS9.0000849028.24492.c6, DOI 10.1097/01.HS9.0000849028.24492.C6]
  • [2] Al-Samkari H., 2022, HEMASPHERE, V6, P1425, DOI [10.1097/01.HS9.0000849032.75798.50, DOI 10.1097/01.HS9.0000849032.75798.50]
  • [3] Mitapivat versus Placebo for Pyruvate Kinase Deficiency
    Al-Samkari, Hanny
    Galacteros, Frederic
    Glenthoj, Andreas
    Rothman, Jennifer A.
    Andres, Oliver
    Grace, Rachael F.
    Morado-Arias, Marta
    Layton, D. Mark
    Onodera, Koichi
    Verhovsek, Madeleine
    Barcellini, Wilma
    Chonat, Satheesh
    Judge, Malia P.
    Zagadailov, Erin
    Xu, Rengyi
    Hawkins, Peter
    Beynon, Vanessa
    Gheuens, Sarah
    van Beers, Eduard J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) : 1432 - 1442
  • [4] Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
    Ataga, K. I.
    Kutlar, A.
    Kanter, J.
    Liles, D.
    Cancado, R.
    Friedrisch, J.
    Guthrie, T. H.
    Knight-Madden, J.
    Alvarez, O. A.
    Gordeuk, V. R.
    Gualandro, S.
    Colella, M. P.
    Smith, W. R.
    Rollins, S. A.
    Stocker, J. W.
    Rother, R. P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (05) : 429 - 439
  • [5] Barcellini W, 2022, HemaSphere, V6, P187, DOI [10.1097/01.HS9.0000844036.02998.15, DOI 10.1097/01.HS9.0000844036.02998.15]
  • [6] Barcellini W., 2022, HEMASPHERE, V6, P1429, DOI [10.1097/01.HS9.0000849048.44424.2a, DOI 10.1097/01.HS9.0000849048.44424.2A]
  • [7] New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy
    Barcellini, Wilma
    Zaninoni, Anna
    Giannotta, Jun Alessandro
    Fattizzo, Bruno
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12) : 1 - 19
  • [8] The Changing Landscape of Autoimmune Hemolytic Anemia
    Barcellini, Wilma
    Fattizzo, Bruno
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [9] Autoimmune Hemolytic Anemias
    Berentsen, Sigbjorn
    Barcellini, Wilma
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) : 1407 - 1419
  • [10] How I treat paroxysmal nocturnal hemoglobinuria
    Brodsky, Robert A.
    [J]. BLOOD, 2021, 137 (10) : 1304 - 1309